1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. Dopamine Receptor

Dopamine Receptor

Dopamine Receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). The neurotransmitter dopamine is the primary endogenous ligand for dopamine receptors. Dopamine receptors are implicated in many neurological processes, including motivation, pleasure, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling. Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. Thus, dopamine receptors are common neurologic drug targets; antipsychotics are often dopamine receptor antagonists while psychostimulants are typically indirect agonists of dopamine receptors. There are at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5. The D1 and D5 receptors are members of the D1-like family of dopamine receptors, whereas the D2, D3 and D4receptors are members of the D2-like family.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-139680
    Dopamine D3 receptor antagonist-1
    Antagonist
    Dopamine D3 receptor antagonist-1 is a dopamine D3 receptor-selective or multitarget bitopic ligand (Ki = 1.58 nM) potentially useful for central nervous system disorders.
    Dopamine D3 receptor antagonist-1
  • HY-100057
    BMY 28674
    Antagonist
    BMY 28674 (6-Hydroxybuspirone) is the active metabolite of the anxiolytic buspirone (HY-B1115A) and is metabolized by CYP3A4.4. BMY 28674 binds to the serotonin (5-HT) receptor subtype 5-HT1A in the rat hippocampus and dorsal raphe (EC50s are 4 and 1 μM, respectively) and is an antagonist of dopamine D2, D3, and D4 receptors (IC50s are 3.1, 4.9, and 0.85 μM, respectively). BMY 28674 also inhibits organic cation transporter 1 (OCT1), OCT2, and OCT3 expressing human transporters in S2 proximal tubule cells in a concentration-dependent manner.
    BMY 28674
  • HY-14544AS
    Quetiapine-d4 hydrochloride
    Antagonist
    Quetiapine-d4 (hydrochloride) (ICI204636-d4 (hydrochloride)) is deuterium labeled Quetiapine. Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects.
    Quetiapine-d<sub>4</sub> hydrochloride
  • HY-W040146R
    Propionylpromazine hydrochloride (Standard)
    Antagonist
    Propionylpromazine (hydrochloride) (Standard) is the analytical standard of Propionylpromazine (hydrochloride). This product is intended for research and analytical applications. Propionylpromazine hydrochloride (Propiopromazine hydrochloride), a dopamine receptor D2 (DRD2) antagonist, can be used in the research of Parkinson disease.
    Propionylpromazine hydrochloride (Standard)
  • HY-W708196
    Dehydrate haloperidol
    Antagonist
    Dehydrohaloperidol, Haloperidol (HY-14538) analogue, is a selective human dopamine D2 receptor antagonist with a pKd of 8 and a pki of 8. Dehydrohaloperidol can be used for the research of schizophrenia.
    Dehydrate haloperidol
  • HY-180814
    SKF-83566-PEG1-pomalidomide
    Antagonist
    SKF-83566-PEG1-pomalidomide is an anti-tumor agent and is formed by the covalent connection of SKF-83566 (HY-103430A) (dopamine D1 receptor antagonist) and Pomalidomide (HY-10984) (immunomodulatory agent). SKF-83566-PEG1-pomalidomide can inhibit cancer cells invasion, migration and colony formation. SKF-83566-PEG1-pomalidomide can inhibit tumor growth and angiogenesis in MDA-MB-231 cell chicken embryo chorioallantoic membrane (CAM) xenograft model. SKF-83566-PEG1-pomalidomide can be used for research of breast cancer.
    SKF-83566-PEG1-pomalidomide
  • HY-10121B
    Asenapine citrate
    Antagonist
    Asenapine citrate, an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine citrate can be used in the research of schizophrenia and bipolar disorder.
    Asenapine citrate
  • HY-15856A
    Flupentixol
    Antagonist
    Flupentixol is an orally active D1/D2 dopamine receptor antagonist and new PI3K inhibitor (PI3Kα IC50=127 nM). Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research.
    Flupentixol
  • HY-13051
    SB-773812
    Antagonist
    SB-773812 is a moderate-affinity antagonist at dopamine receptor 2 (pKi=7.4) and a high-affinity antagonist at the dopamine receptor 3 (pKi=8.5) and at the serotonin 5-hydroxytryptamine receptors 2A (pKi=9.0), 2C (pKi=8.1), and 6 (pKi=8.1). SB-773812 is promising for research of central nervous system disorders.
    SB-773812
  • HY-178103
    D1R antagonist 2
    Antagonist
    D1R antagonist 2 (Compound 13a) is a BBB-penetrable D1R antagonist with IC50s of 35.6 and 70 nM for cAMP-based D1R and β-arrestin-based D1R, respectively. D1R antagonist 2 effectively antagonizes D1R-mediated cAMP and β-arrestin recruitment. D1R antagonist 2 can be used for neurodegenerative and neuropsychiatric diseases such as schizophrenia, Parkinson’s disease and Alzheimer’s disease research.
    D1R antagonist 2
  • HY-139681
    Dopamine D3 receptor antagonist-2
    Antagonist
    Dopamine D3 receptor antagonist-2 is a dopamine D3 receptor-selective (Ki = 2.16 nM) or multitarget bitopic ligand potentially useful for central nervous system disorders.
    Dopamine D3 receptor antagonist-2
  • HY-U00051B
    Propiomazine maleate
    Antagonist
    Propiomazine maleate is an orally active antihistamine agent. Propiomazine maleate is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine maleate is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.
    Propiomazine maleate
  • HY-19372
    SSR-181507 hydrochloride
    Antagonist
    SSR-181507 hydrochloride is a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. SSR-181507 antagonizes Apomorphine (HY-12723)-induced climbing in mice and stereotypies in rats. SSR-181507 hydrochloride can be used in the research of depression and anxiety.
    SSR-181507 hydrochloride
  • HY-123473
    SB-414796
    Antagonist
    SB-414796 is a selective, orally active and cross the blood-brain barrier dopamine D3 receptor antagonist with Ki values of 4, 400 nM for D3, D2, respectively.
    SB-414796
  • HY-149386
    D3R/MOR antagonist 1
    Antagonist
    D3R/MOR antagonist 1 (Compound 114) is a D3R/MOR antagonist (Ki: 46.5 nM and 691 nM respectively). D3R/MOR antagonist 1 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism.
    D3R/MOR antagonist 1
  • HY-16567S
    Asenapine-13C,d3 hydrochloride
    Antagonist
    Asenapine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled Asenapine (hydrochloride). Asenapine hydrochloride, an antipsychotic, is a 5-HT (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and Dopamine (D2, D3, D4) receptor antagonist with Ki values of 0.03-4.0 nM for 5-HT and 1.3, 0.42, 1.1 nM for Dopamine receptor, respectively.
    Asenapine-<sup>13</sup>C,d<sub>3</sub> hydrochloride
  • HY-12697A
    NGB 2904 hydrochloride
    Antagonist
    NGB 2904 hydrochloride is a potent, selective, orally active and brain-penetrated antagonist of dopamine D3 receptor, with a Ki of 1.4 nM. NGB 2904 hydrochloride shows selectivity for D3 over D2, 5-HT2, α1, D4, D1 and D5 receptors (Kis=217, 223, 642, >5000, >10000 and >10000 nM, respectively). NGB 2904 hydrochloride antagonizes Quinpirole-stimulated mitogenesis.
    NGB 2904 hydrochloride
  • HY-173431
    Dopamine D4 receptor ligand 3
    Antagonist
    Dopamine D4 receptor ligand 3 (Compound 16) is a dopamine D4 receptor (D4R) antagonist (pKi: 8.86). Dopamine D4 receptor ligand 3 has pIC50 values of 5.78, 5.55, and 6.17 for Go, Gi, and βArr2 sensors in HEK-293T cells, respectively. Dopamine D4 receptor ligand 3 inhibits the viability of three human glioma cell lines, U87 MG, T98G, and U251 MG. Dopamine D4 receptor ligand 3 induces ROS production and mitochondrial dysfunction in glioma cells.
    Dopamine D4 receptor ligand 3
  • HY-14542S
    Ziprasidone-d8
    Antagonist 98%
    Ziprasidone-d88 is deuterium labeled Ziprasidone, which is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.
    Ziprasidone-d<sub>8</sub>
  • HY-12701
    U-99194
    Antagonist
    U-99194 (PNU-99194) is a selective, potent dopamine D3 receptor antagonist. U-99194 inhibits the activation of D3 receptor mediated by endogenously released dopamine or exogenous D3 agonists. U-99194 abrogates the IPSC-suppressive effect of the D3 agonist PD 128907 in rat hippocampal slices. U-99194 significantly suppresses Nicotine (HY-127019)-induced tremor in mice. U-99194 can be used for the study of dopamine D3 receptor-mediated motor disorders, particularly kinetic tremors.
    U-99194
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.